Citations

Showing 10 of 108152 citations.

Imaging of benign cervicofacial vascular anomalies and associated syndromes
Larson, Anthony S. , Brinjikji, Waleed , Anderson, Katelyn R, Tollefson, Megha M. , Silvera, V. Michelle , Larson, Anthony , Anderson, Katelyn R, Guérin, J.

Mayo Clinic

Interventional Neuroradiology | August 16, 2021 | Volume: 28 | Issue: 3 | Pages: 364-374

10.1177/15910199211034989 | PMID 34397285 Get It

Cervicofacial vascular anomalies can result in morbidity, pain, and cosmetic concerns in affected individuals. Each anomaly has its own unique natural history, treatment, and associations with underlying genetic syndromes. For optimal patient care, it is important for the neuroradiologist to accurately recognize and characterize these entities to ensure appropriate treatment and management. In this review, we discuss the general characteristics, classifications, and imaging features associated with the most common vascular anomalies such as hemangiomas, arteriovenous malformations and fistulas, capillary malformations, venous malformations, and lymphatic malformations in the context of associated syndromes. Additionally, we discuss novel imaging techniques that aid in identifying these vascular anomalies.
Correlation between computed tomography angiography and histology of carotid artery atherosclerosis: Can semi-automated imaging software predict a plaque's composition?
Benson, John C. , Nardi, Valentina , Bois, Melanie C. , Saba, Luca , Brinjikji, Waleed , Savastano, Luis , Benson, John , Nardi, Valentina , Saba, Luca , Lanzino, Giuseppe , Lerman, Amir

Mayo Clinic

Interventional Neuroradiology | August 16, 2021 | Volume: 28 | Issue: 3 | Pages: 332-337

10.1177/15910199211031093 | PMID 34397307 Get It

Background Using computed tomography angiography to differentiate between components of carotid atherosclerotic lesions remains largely elusive. This study sought to validate a semi-automated software for computed tomography angiography plaque analysis using histologic comparisons. Materials and Methods A retrospective review was performed of consecutive patients that underwent a carotid endarterectomy, with pre-procedural computed tomography angiography imaging of the cervical arterial vasculature available for review. Images were evaluated using a commercially-available software package, which produced segmented analyses of intraplaque components (e.g. intraplaque hemorrhage, lipid-rich necrotic core, and calcifications). On imaging, each component was assessed in terms of its (1) presence or absence, and (2) both volume and proportion of the total plaque volume (if present). On histological evaluation of carotid endarterectomy specimens, each component was evaluated as an estimated proportion of total plaque volume. Results Of 80 included patients, 30 (37.5%) were female. The average age was 69.7 years (SD = 9.1). Based on imaging, intraplaque hemorrhage was the smallest contributor to plaque composition (1.2% of volumes on average). Statistically significant linear associations were noted between the proportion of intraplaque hemorrhage, lipid-rich necrotic core, and calcifications on histology and the volume of each component on imaging ( p values ranged from 0.0008 to 0.01). Area under curve were poor for intraplaque hemorrhage and lipid-rich necrotic core (0.59 and 0.61, respectively) and acceptable for calcifications (0.73). Conclusion Semi-automated analyses of computed tomography angiography have limited diagnostic accuracy in the detection of intraplaque hemorrhage and lipid-rich necrotic core in carotid artery plaques. However, volumetric imaging measurements of different components corresponded with histologic analysis.
Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
Shao, Jingwei , Yan, Yuqian , Ding, Donglin , Wang, Dejie , He, Yundong , Pan, Yunqian , Kharbanda, Anupreet , Li, Hongyu , Huang, Haojie , Huang, Rui , Yan, Wei

Mayo Clinic

Advanced Science | August 16, 2021 | Volume: 8 | Issue: 20 | Pages: No page available

10.1002/advs.202102555 | PMID 34397171 Get It

AbstractDNA‐binding proteins, including transcription factors (TFs), play essential roles in various cellular processes and pathogenesis of diseases, deeming to be potential therapeutic targets. However, these proteins are generally considered undruggable as they lack an enzymatic catalytic site or a ligand‐binding pocket. Proteolysis‐targeting chimera (PROTAC) technology has been developed by engineering a bifunctional molecule chimera to bring a protein of interest (POI) to the proximity of an E3 ubiquitin ligase, thus inducing the ubiquitination of POI and further degradation through the proteasome pathway. Here, the development of oligonucleotide‐based PROTAC (O'PROTACs), a class of noncanonical PROTACs in which a TF‐recognizing double‐stranded oligonucleotide is incorporated as a binding moiety of POI is reported. It is demonstrated that O'PROTACs of lymphoid enhancer‐binding factor 1 (LEF1) and ETS‐related gene (ERG), two highly cancer‐related transcription factors, successfully promote degradation of these proteins, impede their transcriptional activity, and inhibit cancer cell growth in vitro and in vivo. The programmable nature of O'PROTACs indicates that this approach is also applicable to destruct other TFs. O'PROTACs not only can serve as a research tool but also can be harnessed as a therapeutic arsenal to target DNA binding proteins for effective treatment of diseases such as cancer.
SDF-1α/OPF/BP Composites Enhance the Migrating and Osteogenic Abilities of Mesenchymal Stem Cells
Li, Linli , Liu, Xifeng , Gaihre, Bipin , Park, Sungjo , Lu, Lichun , Lu, Lichun , Li, Yong , Terzic, André

Mayo Clinic

Stem Cells International | August 16, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-12

10.1155/2021/1938819 | PMID 34434236 Get It

In situ cell recruitment is a promising regenerative medicine strategy with the purpose of tissue regeneration without stem cell transplantation. This chemotaxis-based strategy is aimed at ensuring a restorative environment through the release of chemokines that promote site-specific migration of healing cell populations. Stromal cell-derived factor-1α (SDF-1α) is a critical chemokine that can regulate the migration of mesenchymal stem cells (MSCs). Accordingly, here, SDF-1α-loaded microporous oligo[poly(ethylene glycol) fumarate]/bis[2-(methacryloyloxy)ethyl] phosphate composites (SDF-1α/OPF/BP) were engineered and probed. SDF-1α/OPF/BP composites were loaded with escalating SDF-1α concentrations, namely, 0 ng/ml, 50 ng/ml, 100 ng/ml, and 200 ng/ml, and were cocultured with MSC. Scratching assay, Transwell assay, and three-dimensional migration model were utilized to assess the migration response of MSCs. Immunofluorescence staining of Runx2 and osteopontin (OPN), ELISA assay of osteocalcin (OCN) and alkaline phosphatase (ALP), and Alizarin Red S staining were conducted to assess the osteogenesis of MSCs. All SDF-1α/OPF/BP composites engendered a release of SDF-1α (>80%) during the first four days. SDF-1α released from the composites significantly promoted migration and osteogenic differentiation of MSCs documented by upregulated expression of osteogenic-related proteins, ALP, Runx2, OCN, and OPN. SDF-1α at 100 ng/ml was optimal for enhanced migration and osteogenic proficiency. Thus, designed SDF-1α/OPF/BP composites were competent in promoting the homing and osteogenesis of MSCs and thus offer a promising bioactive scaffold candidate for on-demand bone tissue regeneration.
Mesenchymal stem cells and local tacrolimus delivery synergistically enhance neurite extension
Saffari, Sara , Saffari, Tiam M. , Chan, Katelyn, Shin, Alexander Y. , Chan, K. Ming , Shin, Alexander Y , Chan, Katelyn, Borschel, Gregory Howard

Mayo Clinic

Biotechnology and Bioengineering | August 16, 2021 | Volume: 118 | Issue: 11 | Pages: 4477-4487

10.1002/bit.27916 | PMID 34396506 Get It

AbstractBackgroundThe aim of this study was to investigate the combined effect of mesenchymal stem cells (MSC) and local delivery of tacrolimus (FK506) on nerve regeneration when applied to nerve autografts and decellularized allografts.MethodsA three‐dimensional in vitro compartmented cell culture system consisting of a neonatal dorsal root ganglion adjacent to a nerve graft was used to evaluate the regenerating neurites into the peripheral nerve scaffold. Nerve autografts and allografts were treated with (i) undifferentiated MSCs, (ii) FK506 (100 ng/mL) or (iii) both (N = 9/group). After 48 hours, neurite extension was measured to quantify nerve regeneration and stem cell viability was evaluated.ResultsStem cell viability was confirmed in all MSC‐treated grafts. Neurite extension was superior in autografts treated with FK506, and MSCs and FK506 combined (p < 0.001 and p = 0.0001, respectively), and autografts treated with MSCs (p = 0.12) were comparable to untreated autografts. In allografts, FK506 treatment and combined treatment were superior to controls (p < 0.001 and p = 0.0001, respectively), and treatment with MSCs (p = 0.09) was comparable to controls. All autograft groups were superior compared to their respective allograft treatment group (p < 0.05) in neurite extension.ConclusionsAlone, either MSC or FK506 treatment improved neurite outgrowth, and combined they further enhanced neurite extension in both autografts and allografts.
Heterogeneity in treatment effects across diverse populations
Nugent, Bridget M. , Madabushi, Rajanikanth , Buch, Barbara, Peiris, Vasum, Crentsil, Victor , Miller, Virginia M. , Bull, Jonca, Jenkins, Marjorie

Mayo Clinic

Pharmaceutical Statistics | August 16, 2021 | Volume: 20 | Issue: 5 | Pages: 929-938

10.1002/pst.2161 | PMID 34396690 Get It

Abstract Differences in patient characteristics, including age, sex, and race influence the safety and effectiveness of drugs, biologic products, and medical devices. Here we provide a summary of the topics discussed during the opening panel at the 2018 Johns Hopkins Center for Excellence in Regulatory Science and Innovation symposium on Assessing and Communicating Heterogeneity of Treatment Effects for Patient Subpopulations: Challenges and Opportunities . The goal of this session was to provide a brief overview of FDA‐regulated therapeutics, including drugs, biologics and medical devices, and some of the major sources of heterogeneity of treatment effects (HTE) related to patient demographics, such as age, sex and race. The panel discussed the US Food and Drug Administration's role in reviewing and regulating drugs, devices, and biologic products and the challenges associated with ensuring that diverse patient populations benefit from these therapeutics. Ultimately, ensuring diverse demographic inclusion in clinical trials, and designing basic and clinical research studies to account for the intended patient population's age, sex, race, and genetic factors among other characteristics, will lead to better, safer therapies for diverse patient populations.
Interventional resealing of preterm premature rupture of the membranes: a systematic review and meta-analysis
Ibirogba, Eniola R. , Shazly, Sherif A. , Wahood, Waseem , Trad, Ayssa Teles Abrão , Tsimis, Michael E., Ruano, Rodrigo , Narang, Kavita , Ruano, Rodrigo , Shazly, S A , Ibirogba, Eniola R

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | August 16, 2021 | Volume: 35 | Issue: 25 | Pages: 5978-5992

10.1080/14767058.2021.1903858 | PMID 34392785 Get It

Outcome Measures for Dementia With Lewy Body Clinical Trials
Patel, Bhavana , Kaufer, Daniel , Taylor, Angela , Armstrong, Melissa J. , Armstrong, Melissa J , Irwin, David J. , Boeve, Bradley F.

Mayo Clinic

Alzheimer Disease & Associated Disorders | August 16, 2021 | Volume: 36 | Issue: 1 | Pages: 64-72

10.1097/wad.0000000000000473 | PMID 34393189 Get It

Background: Dementia with Lewy bodies (DLB) is one of the most common degenerative dementias. Clinical trials for individuals with DLB are increasing. We aimed to identify commonly used outcome measures for trials in DLB. Methods: A pragmatic literature search of PubMed and clinicaltrials.gov identified interventional studies including populations with DLB. Studies were included if they enrolled participants with DLB and met the National Institutes of Health criteria for a clinical trial. Data were collected using standardized forms. Outcome measures were categorized according to core and supportive features of DLB. Results: After de-duplication, 58 trials were identified. The most common cognitive outcome measures were the Mini Mental State Examination (n=24) and Cognitive Drug Research computerized Assessment System (n=5). The Clinician’s Assessment of Fluctuations was the most commonly used measure for fluctuations (n=4). Over half of studies used the Neuropsychiatric Inventory to assess behavioral symptoms (n=31). The Unified Parkinson’s Disease Rating Scale was frequently used for motor assessment (n=23). Conclusions and Relevance: Clinical trial outcomes used in DLB are rarely validated in this population and some lack face validity. There is a need to validate existing scales in DLB and develop DLB-specific outcome measures.
Health Care Delivery Interventions for Hypertension Management in Underserved Populations in the United States: A Systematic Review
Pasha, Maarya , Brewer, LaPrincess C. , Sennhauser, Susie , Alsawas, Mouaz , Brewer, LaPrincess C , Alsawas, Mouaz , Murad, M. Hassan

Mayo Clinic

Hypertension | August 16, 2021 | Volume: 78 | Issue: 4 | Pages: 955-965

10.1161/hypertensionaha.120.15946 | PMID 34397275 Get It

The high prevalence of uncontrolled hypertension in underserved populations is a major cause of health disparities in the United States and requires innovative health care delivery interventions. We conducted a systematic review of randomized controlled trials and comparative observational studies examining the effectiveness of contemporary systems change and quality improvement interventions aimed at improving blood pressure (BP) control published from 2010 to 2020. We included studies evaluating multicomponent practice improvement interventions conducted in the United States in community health centers. We identified 26 studies including 48 187 patients with hypertension with a high proportion of racial/ethnic minorities, low socioeconomic status, and a high burden of chronic illness. Multicomponent interventions led to an average reduction of 5 to 10 mm Hg in systolic BP. Four studies demonstrated the effectiveness of integrating pharmacists into community health centers for BP management and reduced cardiovascular disparities for at-risk populations. Five studies demonstrated the effectiveness of integrating community health workers into care workflows leading to reduction in BP and high patient satisfaction. Five studies used the electronic medical record as a tool for population management and showed only modest reduction in BP. One study demonstrated the effectiveness of incentivizing clinics with higher payments for uninsured and Medicaid patients meeting performance criteria. Very few studies evaluated treatment complications or medications side effects. Multicomponent quality improvement interventions instituted in community health centers are effective in lowering BP. Several components of the interventions were identified as being associated with higher efficacy.
IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Chaudhary, Varun , Matonti, Frédéric, Zarranz-Ventura, Javier, Stewart, Michael W., Chaudhary, Varun , Matonti, Frédéric, Zarranz‐Ventura, Javier , Stewart, Michael W.

Mayo Clinic

Retina | August 16, 2021 | Volume: 42 | Issue: 4 | Pages: 589-606

10.1097/iae.0000000000003283 | PMID 34393212 Get It

Purpose: Understanding the impact of fluid in different retinal compartments is critical to developing treatment paradigms that optimize visual acuity and reduce treatment burden in neovascular age-related macular degeneration. This systematic review aimed to determine the impact of persistent/new subretinal fluid, intraretinal fluid, and subretinal pigment epithelial fluid on visual acuity over 1 year of treatment. Methods: Publication eligibility and data extraction were conducted according to Cochrane methods: 27 of the 1,797 screened records were eligible. Results: Intraretinal fluid negatively affected visual acuity at baseline and throughout treatment, with foveal intraretinal fluid associated with lower visual acuity than extrafoveal intraretinal fluid. Some studies found that subretinal fluid (particularly subfoveal) was associated with higher visual acuity at Year 1 and longer term, and others suggested subretinal fluid did not affect visual acuity at Years 1 and 2. Data on the effects of subretinal pigment epithelial fluid were scarce, and consensus was not reached. Few studies reported numbers of injections associated with fluid status. Conclusion: To optimally manage neovascular age-related macular degeneration, clinicians should understand the impact of fluid compartments on visual acuity. After initial treatment, antivascular endothelial growth factor regimens that tolerate stable subretinal fluid (if visual acuity is stable/improved) but not intraretinal fluid may enable patients to achieve their best possible visual acuity. Confirmatory studies are required to validate these findings.